- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01353755
2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma
Randomised Double Blind Placebo Controlled Pivotal Study to Evaluate Efficacy and Safety of rPhleum in Adult and Adolescent Patients Suffering From Rhinoconjunctivitis +/- Controlled Asthma
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Reinbek
-
Hamburg, Reinbek, Germany, 21465
- Allergopharma GmbH & Co. KG
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Has the subject given informed consent according to local requirements before any trial-related activities?
- Is the subject a legally competent male or female outpatient?
- Is the subject aged 12 - 65 year?
Does the subject suffer from IgE-mediated seasonal allergic rhinoconjunctivitis with or without asthma (controlled, acc. to GINA 2006) caused by grass pollen documented by
- skin prick test wheal for grass pollen ≥ 5mm in diameter and
- histamine (1,0% histamindihydrochloride ) wheal ≥ 3mm and
- NaCl control reaction < 3mm and
- EAST result (inhouse Allergopharma) ≥ 1.5kU/L to grass pollens and
- proven clinical relevance of grass pollen allergy by positive conjunctival provocation testing with grass pollen allergens and
- main discomfort in the respective months.
- Does the subject with bronchial asthma at entry have a confirmed diagnosis of asthma and does his asthma has been classified as "controlled" according to GINA guidelines (version 2006) with PEF or FEV1at least 80% of predicted normal?
- Has the subject been treated with anti-allergic medications for at least 2 years prior to enrolment? (Subjects with perennial and continuously treated asthma have to be excluded, see "exclusion criteria" below.)
- For female patients: Does the subject use effective contraception and does she have a negative pregnancy test result? (Highly effective methods of birth control are defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as implants, injectibles, combined or oral contraceptives, some IUDs, sexual abstinence or vasectomised partner. No pharmacological interactions are known for hormonal contraceptives and specific immunotherapeutic preparations.)
- Does the subject suffer from rhinoconjunctivitis symptoms documented in the subjects diary during the baseline season?
- Does the subject have demonstrated a symptom-score of at least 4 per day during the week following the peak pollen count in the baseline season?
Exclusion Criteria:
- Is the subject unable to understand and comply with the requirements of the trial, as judged by the investigator?
- Is the subject currently participating in any other trial or has the subject participated in any other trial within 30 days before inclusion in this trial?
- Is/was the subject involved in the planning and conduct of the trial?
- Is the subject an employee of Allergopharma Joachim Ganzer KG or of one of the trial sites?
- Is the subject in any relationship of dependence with the sponsor and/or with the investigator?
- Has the subject been previously enrolled or randomised to treatment in the present trial?
- Is the subject mentally disabled?
- Is the subject institutionalised due to an official or judicial order?
- Does the subject have a positive pregnancy test before the baseline phase?
- Does the subject use an unacceptable and unreliable contraceptive method during the trial, as judged by the investigator?
- Is the subject pregnant or within the lactation period?
- Is the subject seeking to become pregnant?
- Has the subject undergone previous specific immunotherapy with grass pollen allergens in any formulation?
- Is the subject currently undergoing any sort of immunotherapy?
- Has the subject ever undergone specific immunotherapy with unknown allergen or an unsuccessful immunotherapy?
- For allergens which interfere with the grass pollen season for all participating countries
- Does the subject suffer from any clinically relevant perennial allergies (e.g. cat, mite) and clinical relevance can not be excluded?
- Does the subject show a total IgE of > 2000kU/l?
- Does the subject suffer from clinically relevant rhino-conjunctival or respiratory symptoms related to other reasons?
- Has the subject a PEF or FEV1 < 80% of predicted normal (ECSC)?
- Has the subject uncontrolled or partly controlled asthma according to GINA guidelines (version 2006)?
- Does the subject suffer from perennial and continuously treated asthma?
- Does the subject suffer from rhinoconjunctival atopy symptoms for 20 years or longer?
- Does the subject suffer from severe acute or chronic diseases (e.g. Diabetes mellitus type I, malignant neoplasia, chronic renal failure), severe inflammatory diseases (liver, kidneys)?
- Does the subject suffer from autoimmune diseases, immune-defects including immune-suppression, immune-complex-induced immunopathies?
- Does the subject suffer from severe psychiatric and psychological disorders including impairment of cooperation (e.g. alcohol or drug abuse)?
- Does the subject suffer from recurrent seizures?
- Does the subject suffer from irreversible secondary alterations of the reactive organ (e.g., emphysema, bronchiectasis etc.)?
- Has the subject any physiological and laboratory variables within/outside normal limits and as reported to be greater than Grade 1 changes according to the FDA Guidance for Industry?
- Is the subject treated with beta-blockers (locally and systemically)?
- Has the subject any contraindication for use of adrenalin (e.g., acute or chronic symptomatic coronary heart disease, severe hypertension)?
- Has the subject completed or has an ongoing treatment with anti-IgEantibody?
- Has the subject completed or has an ongoing long-term treatment with tranquilizer or other psychoactive drugs?
- Is the subject treated for allergy or asthma according to severity of symptoms?
- Is the subject using any prophylactic and any treatment with antiallergic medication in fixed (constant) dosage during the treatment phase of the trial?
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: recombinant Phleum (rPhleum) allergen cocktail
The recombinant Phleum (rPhleum) allergen cocktail is prepared by mixing equivalent volumes of each single allergen adsorbate.
The recombinant Phleum (rPhleum) allergen cocktail contains Phleum pratense (Phl p) allergens: Type 1, 2, 5 and 6 at equimolar quatities.
The total protein concentration in the highest strength is 200μg protein per 1mL aluminium hydroxide suspension.
|
The subcutaneous injections will be administered at intervals of 7 (+ 7 days)during up-titration. For maintenance the injection intervals are prolonged to 4 weeks (+2). The double blind treatment period is 2 years, followed by 1 year open-label treatment for patients previously treated with verum and 3 years open-label treatment for patients previously recieved placebo. |
Placebo Comparator: Placebo
Placebo will be administered in the same way as the test product.
Placebo will be identical in terms of appearance to the IMP.
|
Placebo will be administered in the same way as the test product.
Placebo will be identical in terms of appearance to the IMP.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rhinoconjunctivitis Symptom-Medication-Score
Time Frame: 2 years
|
Change of the AUC of the RC-SMS from the baseline season to the season after 2 years of treatment
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
adverse events
Time Frame: entire trial
|
Safety of treatment during the entire trial period will be assessed by clinical laboratory, vital signs and adverse events displayed by MedDRA SOC and Preferred Term.
|
entire trial
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Nicolas Hunzelmann, Prof. Dr.
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AL0906rP
- 2009-011504-36 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Allergic Asthma
-
University of ZurichUniversity of AarhusActive, not recruitingAllergic Rhinitis Due to Grass Pollen | Allergic Rhinitis | Rhinitis, Allergic, Seasonal | Allergic Asthma | Rhinitis; Allergic, With AsthmaSwitzerland
-
Children's Mercy Hospital Kansas CityCompletedAsthma | Allergic Asthma | Non-allergic AsthmaUnited States
-
ALK-Abelló A/SCompletedAllergic Rhinitis Due to House Dust Mite | Allergic Asthma Due to Dermatophagoides Farinae | Allergic Asthma Due to Dermatophagoides PteronyssinusPoland, United Kingdom, Spain, United States, Russian Federation, Hungary, France, Bulgaria, Germany
-
ALK-Abelló A/SITEC ServicesCompletedAllergic Rhinitis Due to House Dust Mite | Allergic Asthma Due to Dermatophagoides Farinae | Allergic Asthma Due to Dermatophagoides PteronyssinusFrance
-
Leti Pharma GmbHCompletedAllergic Asthma | Allergic RhinoconjunctivitisGermany
-
The Cleveland ClinicEnrolling by invitation
-
Inmunotek S.L.BioClever 2005 S.L.; NTS hub S.LNot yet recruitingPerennial Allergic Rhinitis | Allergic Asthma | Allergic Rhinoconjunctivitis | House Dust Mite AllergySpain
-
University Hospital, AkershusOslo University Hospital; ImmunoPharma ASRecruitingAllergic Asthma | Allergic Rhinoconjunctivitis | Immune ToleranceNorway
-
Johann Wolfgang Goethe University HospitalCompleted
-
University of North Carolina, Chapel HillNational Institutes of Health (NIH)TerminatedMild Allergic Rhinitis | Mild Allergic Rhinitis With Mild AsthmaUnited States
Clinical Trials on Grass pollen specific immunotherapy
-
Allergopharma GmbH & Co. KGCompletedGrass Pollen AllergyGermany
-
Johann Wolfgang Goethe University HospitalCompletedHypersensitivity | Allergy | Bronchial Hyperreactivity | Bronchial AsthmaGermany
-
Aarhus University HospitalUniversity of Aarhus; University Hospital, LinkoepingActive, not recruitingAllergic Rhinitis Due to Grass Pollen | Allergic Asthma | Allergic Conjunctivitis of Both EyesDenmark, Sweden
-
Stallergenes GreerCompleted
-
Stallergenes GreerCompletedSeasonal Allergic RhinitisAustria
-
Stallergenes GreerCompleted
-
University Hospital, Strasbourg, FranceCompleted
-
AlyatecCompletedAllergic Rhinitis Due to Grass PollenFrance
-
National Institute of Allergy and Infectious Diseases...Imperial College London; Immune Tolerance Network (ITN)Completed
-
Allergopharma GmbH & Co. KGCompleted